About this trial
Chronic obstructive pulmonary disease (COPD) is complicated by malnutrition in 20-70% of cases. In COPD, low fat-free mass is associated with a higher risk of morbidity and mortality. L-citrulline is a non-protein amino acid that has a direct effect on muscle protein synthesis. Oral supplementation with L-citrulline (10 g/day) in malnourished patients has shown to increase fat-free mass. The effects of L-citrulline supplementation in malnourished COPD patients are unknown.
The main objective of this prospective, single-centre, randomised, double-blind, placebo-controlled study will be to determine the impact of 45 days of nutritional supplementation with L-citrulline (10 g/day) on lean body mass (fat-free mass index (in kg.m-2) measured by bioelectrical impedance analysis) in malnourished patients (BMI \< 20 kg/m2 if \< 70 years old or \< 22 kg/m2 if ≥ 70 years old) with COPD at stages 3-4 of the GOLD classification.
Eligibility criteria
Qualifiers
Men and women aged 50 and over
COPD stage 3 or 4 according to GOLD criteria
BMI < 20 kg/m2 if < 70 years old or < 22 kg/m2 if ≥ 70 years old
Suspicion of sarcopenia marked by a score of 4 or more on the SARC-F questionnaire
Disqualifiers
Main respiratory disease other than COPD
Daily long-term use of systemic corticosteroids (>6 months per year, whatever the dose)
Severe and end-stage renal insufficiency (creatinine clearance <30ml/min)
Patient with severe hypotension, uncontrolled hypertension (at investigator's discretion)
Trial design
Treatments tested in this trial
- L-citrulline